PODD Stock Price Today (October 2026) — Insulet Corporation Analysis & Key Metrics 2026-10-21
Insulet Corporation (PODD) is trading at $142.64, up 0.48% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $167.17 (17.2% upside).
- Volatility is low (24.36% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.50% YoY) alongside competitive pressures in the Medical Devices space.
PODD Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Insulet Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $10.31B
P/E Ratio
Forward P/E: 19.28
Revenue Growth
Year over Year
Analyst Target
+17.2% upside potential
Key Investor Questions About PODD
What investors need to know before buying
Based on current market data, PODD presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 60.28)
- Fundamentals say: Looking solid (debt and growth supportive)
PODD's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PODD investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $948.40M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, PODD stock traded between $126.40 and $354.88 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.36% annualized volatility and β=0.34, the stock exhibits low sensitivity to market moves—making PODD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
2 Profitable Stocks to Keep an Eye On and 1 We Question
2 of Wall Street’s Favorite Stocks to Target This Week and 1 We Ignore
Insulet Announces Omnipod Discover Now Available in U.S.
Leerink Partners Adjusts Insulet Price Target to $143 From $145
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
Latest TickZen Insights
All insights →No TickZen article on PODD yet. Our newest analysis:
Explore More Analysis for PODD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026
Frequently Asked Questions
Common investor questions about Insulet Corporation
Insulet Corporation (PODD) is currently trading at $142.64. The RSI (14-day) is at 60.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $167.17 implies 17.2% upside from current levels. Volatility is moderate at 24.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insulet Corporation (PODD): The trailing P/E ratio is 25.85, which is in line with broader market averages. The forward P/E is 19.28, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.44, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.72. Price-to-Sales is 3.13. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering PODD, the consensus price target is $167.17. This represents a 17.2% upside from the current price of $142.64. The range spans from a low target of $143.00 to a high target of $215.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insulet Corporation (PODD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insulet Corporation (PODD) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insulet Corporation's (PODD) current debt and financial health profile: Total debt stands at $948.40M. The debt-to-equity ratio is 0.67x, which is moderate and generally manageable for most companies. The current ratio is 2.49, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $534.90M in cash and equivalents. Free cash flow is positive at $236.90M, providing a cushion for debt servicing and shareholder returns.